
Stephen D. Rosasco
Examiner (ID: 4235, Phone: (571)272-1389 , Office: P/1721 )
| Most Active Art Unit | 1756 |
| Art Unit(s) | 1507, 1795, 1721, 1752, 1737, 1756, 1113 |
| Total Applications | 2769 |
| Issued Applications | 2461 |
| Pending Applications | 68 |
| Abandoned Applications | 246 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17154952
[patent_doc_number] => 20210316003
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-14
[patent_title] => BIOMARKERS FOR SACITUZUMAB GOVITECAN THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/206388
[patent_app_country] => US
[patent_app_date] => 2021-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35191
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17206388
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/206388 | BIOMARKERS FOR SACITUZUMAB GOVITECAN THERAPY | Mar 18, 2021 | Abandoned |
Array
(
[id] => 20159301
[patent_doc_number] => 12385922
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-12
[patent_title] => Size-based gating to analyze flow cytometry data
[patent_app_type] => utility
[patent_app_number] => 17/203832
[patent_app_country] => US
[patent_app_date] => 2021-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 20
[patent_no_of_words] => 7345
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 248
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17203832
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/203832 | Size-based gating to analyze flow cytometry data | Mar 16, 2021 | Issued |
Array
(
[id] => 18272023
[patent_doc_number] => 20230093265
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => NEW METHOD AND COMPOUND FOR PROSTATE CANCER DIAGNOSIS
[patent_app_type] => utility
[patent_app_number] => 17/908291
[patent_app_country] => US
[patent_app_date] => 2021-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22269
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17908291
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/908291 | NEW METHOD AND COMPOUND FOR PROSTATE CANCER DIAGNOSIS | Feb 28, 2021 | Pending |
Array
(
[id] => 18452069
[patent_doc_number] => 20230193348
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => DPP3 FOR THERAPY GUIDANCE, MONITORING AND STRATIFICATION OF NT-ADM ANTIBODIES IN PATIENTS WITH SHOCK
[patent_app_type] => utility
[patent_app_number] => 17/802799
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24316
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17802799
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/802799 | DPP3 FOR THERAPY GUIDANCE, MONITORING AND STRATIFICATION OF NT-ADM ANTIBODIES IN PATIENTS WITH SHOCK | Feb 25, 2021 | Pending |
Array
(
[id] => 17005450
[patent_doc_number] => 20210236611
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => COMPOSITION AND PROCESS FOR PREPARING VACCINE
[patent_app_type] => utility
[patent_app_number] => 17/249362
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 69706
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17249362
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/249362 | COMPOSITION AND PROCESS FOR PREPARING VACCINE | Feb 25, 2021 | Abandoned |
Array
(
[id] => 17719109
[patent_doc_number] => 20220211828
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => TARGET PEPTIDES FOR OVARIAN CANCER THERAPY AND DIAGNOSTICS
[patent_app_type] => utility
[patent_app_number] => 17/182886
[patent_app_country] => US
[patent_app_date] => 2021-02-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28882
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17182886
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/182886 | TARGET PEPTIDES FOR OVARIAN CANCER THERAPY AND DIAGNOSTICS | Feb 22, 2021 | Abandoned |
Array
(
[id] => 17036706
[patent_doc_number] => 20210253664
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => TLR9 LIGAND TRAP
[patent_app_type] => utility
[patent_app_number] => 17/181246
[patent_app_country] => US
[patent_app_date] => 2021-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11535
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17181246
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/181246 | TLR9 ligand trap | Feb 21, 2021 | Issued |
Array
(
[id] => 20264180
[patent_doc_number] => 12435156
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-07
[patent_title] => Methods for treating neuroblastoma with combination therapy
[patent_app_type] => utility
[patent_app_number] => 17/181321
[patent_app_country] => US
[patent_app_date] => 2021-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12051
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 248
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17181321
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/181321 | Methods for treating neuroblastoma with combination therapy | Feb 21, 2021 | Issued |
Array
(
[id] => 17052605
[patent_doc_number] => 20210262039
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => MOLECULAR BIOMARKERS FOR CANCER IMMUNOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 17/179956
[patent_app_country] => US
[patent_app_date] => 2021-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 71501
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17179956
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/179956 | Molecular biomarkers for cancer immunotherapy | Feb 18, 2021 | Issued |
Array
(
[id] => 17036759
[patent_doc_number] => 20210253717
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => Treatment of Patients Having c-Met Exon 14 Skipping Mutations
[patent_app_type] => utility
[patent_app_number] => 17/174386
[patent_app_country] => US
[patent_app_date] => 2021-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28091
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -47
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17174386
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/174386 | Treatment of patients having c-met exon 14 skipping mutations | Feb 11, 2021 | Issued |
Array
(
[id] => 18484977
[patent_doc_number] => 20230212292
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => USE OF ANTI-PD-1 ANTIBODY IN TREATING NEUROENDOCRINE TUMORS
[patent_app_type] => utility
[patent_app_number] => 17/904098
[patent_app_country] => US
[patent_app_date] => 2021-02-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11689
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17904098
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/904098 | USE OF ANTI-PD-1 ANTIBODY IN TREATING NEUROENDOCRINE TUMORS | Feb 9, 2021 | Abandoned |
Array
(
[id] => 17275859
[patent_doc_number] => 20210382057
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => DETECTION OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) EXPRESSION ON CIRCULATING TUMOR CELLS (CTC)
[patent_app_type] => utility
[patent_app_number] => 17/170769
[patent_app_country] => US
[patent_app_date] => 2021-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11749
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17170769
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/170769 | DETECTION OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) EXPRESSION ON CIRCULATING TUMOR CELLS (CTC) | Feb 7, 2021 | Abandoned |
Array
(
[id] => 17200161
[patent_doc_number] => 20210340256
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => Gene Signatures for Determining ICOS Expression
[patent_app_type] => utility
[patent_app_number] => 17/168544
[patent_app_country] => US
[patent_app_date] => 2021-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62555
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17168544
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/168544 | Gene Signatures for Determining ICOS Expression | Feb 4, 2021 | Abandoned |
Array
(
[id] => 18244326
[patent_doc_number] => 20230076637
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-09
[patent_title] => FUSION ANTIBODY FOR PRESENTING ANTIGEN-DERIVED T CELL ANTIGEN EPITOPE OR PEPTIDE CONTAINING SAME ON CELL SURFACE, AND COMPOSITION COMPRISING SAME
[patent_app_type] => utility
[patent_app_number] => 17/796788
[patent_app_country] => US
[patent_app_date] => 2021-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34988
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17796788
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/796788 | FUSION ANTIBODY FOR PRESENTING ANTIGEN-DERIVED T CELL ANTIGEN EPITOPE OR PEPTIDE CONTAINING SAME ON CELL SURFACE, AND COMPOSITION COMPRISING SAME | Feb 4, 2021 | Pending |
Array
(
[id] => 20465400
[patent_doc_number] => 12521429
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-13
[patent_title] => Zika virus immunogenic compositions
[patent_app_type] => utility
[patent_app_number] => 17/797662
[patent_app_country] => US
[patent_app_date] => 2021-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 47
[patent_no_of_words] => 7316
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17797662
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/797662 | Zika virus immunogenic compositions | Feb 3, 2021 | Issued |
Array
(
[id] => 19296397
[patent_doc_number] => 20240224960
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-11
[patent_title] => PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/167578
[patent_app_country] => US
[patent_app_date] => 2021-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15523
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17167578
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/167578 | PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF | Feb 3, 2021 | Pending |
Array
(
[id] => 18240217
[patent_doc_number] => 20230072528
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-09
[patent_title] => METHODS FOR DISCONTINUING A TREATMENT WITH A TYROSINE KINASE INHIBITOR (TKI)
[patent_app_type] => utility
[patent_app_number] => 17/760202
[patent_app_country] => US
[patent_app_date] => 2021-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16323
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17760202
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/760202 | METHODS FOR DISCONTINUING A TREATMENT WITH A TYROSINE KINASE INHIBITOR (TKI) | Feb 3, 2021 | Abandoned |
Array
(
[id] => 16853539
[patent_doc_number] => 20210154284
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-27
[patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NHL AND OTHER CANCERS
[patent_app_type] => utility
[patent_app_number] => 17/165457
[patent_app_country] => US
[patent_app_date] => 2021-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39567
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17165457
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/165457 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NHL AND OTHER CANCERS | Feb 1, 2021 | Abandoned |
Array
(
[id] => 17043828
[patent_doc_number] => 11096988
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-08-24
[patent_title] => CD80 variant immunomodulatory proteins and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/161593
[patent_app_country] => US
[patent_app_date] => 2021-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 34
[patent_no_of_words] => 122371
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17161593
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/161593 | CD80 variant immunomodulatory proteins and uses thereof | Jan 27, 2021 | Issued |
Array
(
[id] => 17293460
[patent_doc_number] => 20210389299
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => METHODS AND COMPOSITIONS FOR CHARACTERIZATION OF GLIOBLASTOMA MULTIFORME TUMORS AND CANCER STEM CELLS
[patent_app_type] => utility
[patent_app_number] => 17/153198
[patent_app_country] => US
[patent_app_date] => 2021-01-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9648
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17153198
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/153198 | METHODS AND COMPOSITIONS FOR CHARACTERIZATION OF GLIOBLASTOMA MULTIFORME TUMORS AND CANCER STEM CELLS | Jan 19, 2021 | Abandoned |